Skip to main content

#160389

Tin Tungstate Nanoparticles Beta-SnWO4 small molecule (tool compound)

Cat. #160389

Tin Tungstate Nanoparticles Beta-SnWO4 small molecule (tool compound)

Cat. #: 160389

Sub-type: Nanoparticle

Availability: Please enquire for quantities and pricing

Application: Used to treat tumours in BALB/C mice orthotopically inoculated with the 4T1 breast cancer cell line. Reduced lymph node metastases.Killed 4T1 cells in vitro.

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Claus Feldmann

Institute: Karlsruhe Institute of Technology

Tool Details
Handling
Target Details
Application Details
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Tool name: Tin Tungstate Nanoparticles Beta-SnWO4 small molecule (tool compound)
  • Cancer: Breast cancer;Skin cancer
  • Cancers detailed: Breast cancer;Colon;Esophageal;Gastric;Skin cancer
  • Research fields: Cancer;Metabolism
  • Tool sub type: Nanoparticle
  • Primary target: Near-surface tumours
  • Description: Tin Tungstate nanoparticles act as photosensitizers for photodynamic tumor therapy of near-surface tumors via reiterated 5 min blue-light LED illumination.
  • Application: Used to treat tumours in BALB/C mice orthotopically inoculated with the 4T1 breast cancer cell line. Reduced lymph node metastases.Killed 4T1 cells in vitro.
  • Additional notes: "The nanoparticulate inorganic photosensitizer β-SnWO4 is suggested for photodynamic therapy (PDT) of near-surface tumors via reiterated 5 min blue-light LED illumination. β-SnWO4 nanoparticles are obtained via water-based synthesis and comprise excellent colloidal stability under physiological conditions and high biocompatibility at low material complexity. Antitumor and antimetastatic effects were investigated with a spontaneously metastasizing (4T1 cells) orthotopic breast cancer BALB/c mouse model. Besides protamine-functionalized β-SnWO4 (23 mg/kg of body weight, in PBS buffer), chemotherapeutic doxorubicin was used as positive control (2.5 mg/kg of body weight, in PBS buffer) and physiological saline (DPBS) as a negative control. After 21 days, treatment with β-SnWO4 resulted in a clearly inhibited growth of the primary tumor (all tumor volumes below 3 cm3) as compared to the doxorubicin and DPBS control groups (volumes up to 6 cm3). Histological evaluations of lymph nodes and lungs as well as the volume of ipsilateral lymph nodes show a remarkable antimetastatic effect being similar to chemotherapeutic doxorubicin butaccording to blood countsat significantly reduced side effects. On the basis of low material complexity, high cytotoxicity under blue-light LED illumination at low dark and long-term toxicity, β-SnWO4 can be an interesting addition to PDT and the treatment of near-surface tumors, including skin cancer, esophageal/gastric/colon tumors as well as certain types of breast cancer." From Seidl et al 2016, ACS Nano, 10, 3149−3157.

Handling

  • Shipping conditions: Dry Ice

Target Details

  • Primary target: Near-surface tumours

Application Details

  • Application: Used to treat tumours in BALB/C mice orthotopically inoculated with the 4T1 breast cancer cell line. Reduced lymph node metastases.Killed 4T1 cells in vitro.

References

  • Seidl et al. 2016. ACS Nano. 10(3):3149-57. PMID: 26894966.
  • Ungelenk et al. 2014. Chem Commun (Camb). 50(50):6600-3. PMID: 24824575.
  • Ungelenk et al. 2012. Chem Commun (Camb). 48(63):7838-40. PMID: 22735092.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.